Home Overview Research Programs Shared Facilities News & Outreach Technology Transfer Employment About PHRI

Scientific Overview Research Interest Summary Principal Investigators    Yuri Bushkin, Ph.D.
   Theresa Chang, Ph.D.
   Neeraj Chauhan, Ph.D.
   Véronique Dartois, Ph.D.
   Thomas Dick, Ph.D.
   Karl Drlica, Ph.D.
   David Dubnau, Ph.D.
   Eliseo A. Eugenin, Ph.D.
   Marila Gennaro, M.D.
   Fred Kramer, Ph.D.
   Barry Kreiswirth, Ph.D.
   Min Lu, Ph.D.
   Leonard Mindich, Ph.D.
   Arkady Mustaev, Ph.D.
   Jyothi Nagajyothi, Ph.D.
   David Perlin, Ph.D.
   Abraham Pinter, Ph.D.
   Marcela Rodriguez, Ph.D.
   Lanbo Shi, Ph.D.
   Selvakumar Subbian, Ph.D.
   Sanjay Tyagi, Ph.D.
   Christopher Vinnard, M.D.
   Chaoyang Xue, Ph.D.
   Xilin Zhao, Ph.D.

   Research Faculty
   Liang Chen, Ph.D.
   Eugenie Dubnau, Ph.D.
   Jeanette Hahn, Ph.D.
   Salvatore Marras, Ph.D.
   Yanan Zhao, Ph.D.

Emeritus Faculty Recent Publications
Karl Drlica, Ph.D.

Research Summary  |  Selected Publications  |  Book Chapters
Symposium Chapters  |  Books Authored  |  Books Edited
Other Sponsored Work


Public Health Research Institute Center
New Jersey Medical School - Rutgers, The State University of New Jersey
225 Warren Street
Newark, New Jersey 07103

Phone: (917) 821-6847
e-mail: drlicaka@njms.rutgers.edu

Research Summary

Overview.  Dr. Drlica’s work addresses the general problem of antibiotic resistance. Drlica and Dr. Xilin Zhao at PHRI formulated the mutant selection window hypothesis as a framework for understanding relationships between antimicrobial concentration and selective enrichment of mutant subpopulations. Expansion of these sub-populations is thought to lead to new resistance. The work also seeks to understand how some antimicrobials rapidly kill bacteria to facilitate the design of compounds that quickly lower pathogen burden during infection. This type of work is expected to be important, because current antimicrobial use is based on a bacteriostatic measurement (MIC) rather than on killing. Lethal action is expected to be significant when antimicrobial consumption is high and immune-suppression is widespread, as is currently the case.

Fluoroquinolone resistance.  The Drlica laboratory is working on two general aspects of fluoroquinolone resistance. One is to develop new derivatives that bypass existing quinolone-resistance mutations. The quinazolinediones are one example. These compounds lack a stabilizing interaction with DNA gyrase that makes them invulnerable to GyrA resistance mutations. Other stabilizing interactions have been found that improve activity. Another example are C7 aryl fluoroquinolones. These agents appear to bind more avidly to a secondary binding mode than commercially available fluoroquinolones.

The second aspect of resistance concerns identifying antibiotic doses that restrict the emergence of resistance. Early work showed that resistant bacterial mutants are selectively enriched when drug concentrations fall inside a range called the mutant selection window. The selection window idea has now been tested with fluctuating drug concentrations in vitro and in an animal model with Staphylococcus aureus. The hypothesis has also passed a small clinical test in which S. aureus resistance developed at the same time susceptible populations were eradicated. Moreover, the hypothesis explains why clinical resistance is higher with some macrolides than with others.

The selection window hypothesis reveals a fundamental flaw in our current antimicrobial dosing strategies: almost all antimicrobial treatment protocols place drug concentrations inside the selection window for long periods of time. Restricting the emergence of resistance requires increasing doses in addition to the accepted practice of reducing unnecessary use. Persons interested in early selection window publications are referred to MSW papers 

Fluoroquinolone lethality.  A second line of laboratory study focuses on quinolone-mediated killing of bacteria, particularly non-growing cells of species such as Mycobacterium tuberculosis. The fluoroquinolones trap DNA gyrase on bacterial DNA as ternary complexes in which the DNA is broken. Rapid cell death correlates with chromosome fragmentation, which is thought to arise from release of DNA breaks from the ternary complexes. The Drlica laboratory has identified a new quinolone-binding mode in ternary complexes that may be a key to understanding why rapidly lethal concentrations are higher than those needed to block growth. Ongoing collaborations are with Xilin Zhao (PHRI), Robert Kerns (U. of Iowa), James Berger (Johns Hopkins Medical School), Hiroshi Hiasa (U. of Minnesota), and Arkady Mustaev (PHRI).

Bacterial self-destruction.  Drlica is also collaborating with Xilin Zhao (PHRI) to understand bacterial self-destruction associated with lethal antimicrobials. Focus is on the connection between bacterial lesions caused by antibacterials and a cascade of reactive oxygen species thought to kill bacteria even after the initial stress is removed. One aim of this effort is to develop small-molecule enhancers of antimicrobials.

Honors and Awards

NIH Research Career Development Award
Holmes Memorial Lecture (Florida Institute of Technology)
Heikkila Memorial Lecture (University of Medicine and Dentistry of New Jersey)
Alumni Fellow (Oregon State University)
Christopher Mathews Lecture (Oregon State University)
Professional Night Speaker (College Board Reviewers)
Mentor of the Year (New Jersey Medical School, UMDNJ)

Selected Publications

Mi H, Wang D, Xue Y, Zhang Z, Niu J, Hong Y, Drlica K, Zhao X (2016) Dimethyl sulfoxide protects Escherichia coli from rapid antimicrobial-mediated killing. Antimicrob Agents Chemother.. Antimicrob. Agents Chemother. 60: 5954-5958. PMI:

Malik M, Mustaev A, Schwanz H, Luan G, Shah N, Oppegard L, deSouza E, Hiasa H, Zhao X, Kerns R, Drlica K (2016) Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. Nucleic Acids Res 44: 3304-3316. PMI:

Liu Y, Zhou J, Qu Y, Yang X, Shi G, Wang X, Hong Y, Drlica K, Zhao X (2016) Resveratrol antagonizes antimicrobial lethality and stimulates recovery of bacterial mutants. . PlosOne 11: e0153023. PMI:

Zhao X, Hong Y, Drlica K (2015) Moving forward with ROS involvement in antimicrobial lethality. J Antimicrob Chemother 70: 639-642. PMI:

Long Q, Du Q, Fu T, Drlica K, Zhao X, Xie J (2015) Involvement of Holliday junction resolvase in fluoroquinolone-mediated killing of Mycobacterium smegmatis. . Antimicrob. Agents Chemother. 59: 1782-1785. PMI:

Hesje C, Drlica K, Blondeau J (2015) Mutant prevention concentration for tigecycline with clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus J Antimicrob Chemother 70: 494-497. PMI:

Zhao X, Drlica K (2014) Reactive oxygen species and the bacterial response to lethal stress. . Current Opinion in Microbiology 21: 1-6. PMI:

Mustaev A, Malik M, Zhao X, Kurepina N, Luan G, Oppegard LM, Hiasa H, Marks KR, Kerns RJ, Berger JM, Drlica K (2014) Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J. Biol. Chem 289: 12300-12312. PMI:

Malik M, Li L, Zhao X, Kerns RJ, Berger JM, Drlica K (2014) Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics. . J. Antimicrob Chemother. 89 3227-3235. PMI:

Li L, Hong Y, Luan G, Mosel M, Malik M, Drlica K, Zhao X (2014) Ribosomal elongation factor-4 promotes cell death associated with lethal stress. mBio 5: e01708 PMI:

Drlica K, Mustaev A, Towle T, Luan G, Kerns R, Berger J (2014) Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. . ACS Chemical Biology 9: 2895-2904. PMI:

Mosel M, Li L, Drlica K, Zhao X (2013) Superoxide-mediated protection of Escherichia coli from antimicrobials. Antimicrob Agents Chemother 57: 5755-5759. PMI: 23979754

Metzler K, Drlica K, Blondeau JM (2013) Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 68: 631-635. PMI: 23169894

Dorsey-Oresto A, Lu T, Mosel M, Wang X, Salz T, Drlica K, Zhao X (2013) YihE kinase is a central regulator of programmed cell death in bacteria. Cell Rep 3: 528-537. PMI: 23416055

Malik M, Chavda K, Zhao X, Shah N, Hussain S, Kurepina N, Kreiswirth BN, Kerns RJ, Drlica K (2012) Induction of mycobacterial resistance to quinolone class antimicrobials. Antimicrob Agents Chemother 56: 3879-3887. PMI: 22564842

Wu X, Wang X, Drlica K, Zhao X (2011) A toxin-antitoxin module in Bacillus subtilis can both mitigate and amplify effects of lethal stress. PLoS One 6: e23909. PMI: 21897862

Marks KR, Malik M, Mustaev A, Hiasa H, Drlica K, Kerns RJ (2011) Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones. Bioorg Med Chem Lett 21: 4585-4588. PMI: 21705218

Malik M, Marks KR, Mustaev A, Zhao X, Chavda K, Kerns RJ, Drlica K (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother 55: 2335-2343. PMI: 21383100

Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X (2011) Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother 55: 2409-2412. PMI: 21343454

Wang X, Zhao X, Malik M, Drlica K (2010) Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J Antimicrob Chemother 65: 520-524. PMI: 20067982

Oppegard LM, Streck KR, Rosen JD, Schwanz HA, Drlica K, Kerns RJ, Hiasa H (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones. Antimicrob Agents Chemother 54: 3011-3014. PMI: 20404126

Malik M, Marks KR, Schwanz HA, German N, Drlica K, Kerns RJ (2010) Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. Antimicrob Agents Chemother 54: 5214-5221. PMI: 20855738

Malik M, Hoatam G, Chavda K, Kerns RJ, Drlica K (2010) Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob Agents Chemother 54: 149-156. PMI: 19805561

Han X, Dorsey-Oresto A, Malik M, Wang JY, Drlica K, Zhao X, Lu T (2010) Escherichia coli genes that reduce the lethal effects of stress. BMC Microbiol 10: 35. PMI: 20128927

Malik M, Capecci J, Drlica K (2009) Lon protease is essential for paradoxical survival of Escherichia coli exposed to high concentrations of quinolone. Antimicrob Agents Chemother 53: 3103-3105. PMI: 19414573

Hussain S, Malik M, Shi L, Gennaro ML, Drlica K (2009) In vitro model of mycobacterial growth arrest using nitric oxide with limited air. Antimicrob Agents Chemother 53: 157-161. PMI: 18955516

Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X (2009) Quinolones: action and resistance updated. Curr Top Med Chem 9: 981-998. PMI: 19747119

Burger RM, Drlica K (2009) Superoxide protects Escherichia coli from bleomycin mediated lethality. J Inorg Biochem 103: 1273-1277. PMI: 19679357

Zhao X, Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemother 62: 434-436. PMI: 18544596

Usongo V, Nolent F, Sanscartier P, Tanguay C, Broccoli S, Baaklini I, Drlica K, Drolet M (2008) Depletion of RNase HI activity in Escherichia coli lacking DNA topoisomerase I leads to defects in DNA supercoiling and segregation. Mol Microbiol 69: 968-981. PMI: 18554330

German N, Malik M, Rosen JD, Drlica K, Kerns RJ (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones. Antimicrob Agents Chemother 52: 3915-3921. PMI: 18765690

Drlica K, Zhao X, Kreiswirth B (2008) Minimising moxifloxacin resistance with tuberculosis. Lancet Infect Dis 8: 273-275. PMI: 18471768

Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52: 385-392. PMI: 17724149

Baaklini I, Usongo V, Nolent F, Sanscartier P, Hraiky C, Drlica K, Drolet M (2008) Hypernegative supercoiling inhibits growth by causing RNA degradation. J Bacteriol 190: 7346-7356. PMI: 18790862

Ye F, Brauer T, Niehus E, Drlica K, Josenhans C, Suerbaum S (2007) Flagellar and global gene regulation in Helicobacter pylori modulated by changes in DNA supercoiling. Int J Med Microbiol 297: 65-81. PMI: 17276136

Quinn B, Hussain S, Malik M, Drlica K, Zhao X (2007) Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 60: 1380-1383. PMI: 17905797

Malik M, Hussain S, Drlica K (2007) Effect of anaerobic growth on quinolone lethality with Escherichia coli. Antimicrob Agents Chemother 51: 28-34. PMI: 17043118

Drlica K, Zhao X (2007) Mutant selection window hypothesis updated. Clin Infect Dis 44: 681-688. PMI: 17278059

Zhao X, Quinn B, Kerns R, Drlica K (2006) Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 58: 1283-1286. PMI: 17003060

Zhao X, Malik M, Chan N, Drlica-Wagner A, Wang JY, Li X, Drlica K (2006) Lethal action of quinolones against a temperature-sensitive dnaB replication mutant of Escherichia coli. Antimicrob Agents Chemother 50: 362-364. PMI: 16377712

Singh A, Singh Y, Pine R, Shi L, Chandra R, Drlica K (2006) Protein kinase I of Mycobacterium tuberculosis: cellular localization and expression during infection of macrophage-like cells. Tuberculosis (Edinb) 86: 28-33. PMI: 16256441

Malik M, Zhao X, Drlica K (2006) Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol Microbiol 61: 810-825. PMI: 16803589

Malik M, Drlica K (2006) Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob Agents Chemother 50: 2842-2844. PMI: 16870782

Hansen GT, Zhao X, Drlica K, Blondeau JM (2006) Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 27: 120-124. PMI: 16426820

Drlica K, Zhao X, Blondeau JM, Hesje C (2006) Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 50: 403-404. PMI: 16377725

Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X (2006) The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 194: 1601-1608. PMI: 17083047

Wehbeh W, Rojas-Diaz R, Li X, Mariano N, Grenner L, Segal-Maurer S, Tommasulo B, Drlica K, Urban C, Rahal JJ (2005) Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother 49: 2495-2497. PMI: 15917553

Malik M, Lu T, Zhao X, Singh A, Hattan CM, Domagala J, Kerns R, Drlica K (2005) Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrob Agents Chemother 49: 2008-2014. PMI: 15855526

Liu Y, Cui J, Wang R, Wang X, Drlica K, Zhao X (2005) Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 56: 1172-1175. PMI: 16207765

Wang JY, Drlica K (2004) Computational identification of antisense oligonucleotides that rapidly hybridize to RNA. Oligonucleotides 14: 167-175. PMI: 15625912

Shopsin B, Zhao X, Kreiswirth BN, Tillotson GS, Drlica K (2004) Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Int J Antimicrob Agents 24: 32-34. PMI: 15225857

Metzler K, Hansen GM, Hedlin P, Harding E, Drlica K, Blondeau JM (2004) Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24: 161-167. PMI: 15288315

Li X, Mariano N, Rahal JJ, Urban CM, Drlica K (2004) Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother 48: 3570-3572. PMI: 15328129

Li X, Mariano N, Rahal JJ, Urban CM, Drlica K (2004) Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 48: 4460-4462. PMI: 15504883

Etienne M, Croisier D, Charles PE, Lequeu C, Piroth L, Portier H, Drlica K, Chavanet P (2004) Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J Infect Dis 190: 1472-1475. PMI: 15378440

Epstein BJ, Gums JG, Drlica K (2004) The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother 38: 1675-1682. PMI: 15340128

Drlica K, Zhao X (2004) Is "dosing-to-cure" appropriate in the face of antimicrobial resistance? Reviews in Medical Microbiology 15: 73-80. PMI: 0

Zinner SH, Lubenko IY, Gilbert D, Simmons K, Zhao X, Drlica K, Firsov AA (2003) Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 52: 616-622. PMI: 12951352

Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K (2003) Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 47: 1023-1027. PMI: 12604537

Wang JY, Drlica K (2003) Modeling hybridization kinetics. Math Biosci 183: 37-47. PMI: 12604134

Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K (2003) Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 52: 61-64. PMI: 12805268

Lu T, Drlica K (2003) In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028. PMI: 14613961

Hansen GT, Metzler K, Drlica K, Blondeau JM (2003) Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 47: 440-441. PMI: 12499234

Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH (2003) In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47: 1604-1613. PMI: 12709329

Drlica K, Zhao X (2003) Fluoroquinolone-resistant Streptococcus pneumoniae. Reviews in Medical Microbiology 14: 1-9. PMI: 0

Drlica K, Malik M (2003) Fluoroquinolones: action and resistance. Curr Top Med Chem 3: 249-282. PMI: 12570763

Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17. PMI: 12805267

Chopra P, Singh A, Koul A, Ramachandran S, Drlica K, Tyagi AK, Singh Y (2003) Cytotoxic activity of nucleoside diphosphate kinase secreted from Mycobacterium tuberculosis. Eur J Biochem 270: 625-634. PMI: 12581202

Zhao X, Drlica K (2002) Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 185: 561-565. PMI: 11865411

Tillotson GS, Zhao X, Drlica K (2002) Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 347: 65-67; author reply 65-67. PMI: 12102062

Li X, Zhao X, Drlica K (2002) Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 46: 522-524. PMI: 11796368

Drlica K, Schmitz FJ (2002) Therapeutic options in an era of decreasing antimicrobial susceptibility. J Chemother 14 Suppl 2: 5-12. PMI: 12003139

Zhao X, Drlica K (2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33 Suppl 3: S147-156. PMI: 11524712

Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, Rahal JJ (2001) Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 184: 794-798. PMI: 11517444

Tillotson G, Zhao X, Drlica K (2001) Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Infect Dis 1: 145-146. PMI: 11871490

Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, Drlica K (2001) Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 45: 2703-2709. PMI: 11557458

Koul A, Choidas A, Tyagi AK, Drlica K, Singh Y, Ullrich A (2001) Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: characterization and localization. Microbiology 147: 2307-2314. PMI: 11496007

Heddle JG, Lu T, Zhao X, Drlica K, Maxwell A (2001) gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity. J Mol Biol 309: 1219-1231. PMI: 11399091

Friedman SM, Lu T, Drlica K (2001) Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother 45: 2378-2380. PMI: 11451702

Drlica K (2001) Antibiotic resistance: can we beat the bugs? Drug Discov Today 6: 714-715. PMI: 11445459

Blondeau JM, Zhao X, Hansen G, Drlica K (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 433-438. PMI: 11158737

Book Chapters

Drlica, K, Zhao, X, Malik, M, Salz, Tal, and Kerns R (2012). Fluoroquinolone Resistance: Mechanisms, Restrictive Dosing, and Anti-mutant Screening Strategies for New Compouds. In Antibiotic Discovery and Development, T Dougherty and M Pucci Ed., Springer New York, Dordrecht, Heidelberg, London.

Drlica, K., and Bendich, A. (2009) Chromosome, Bacterial In Encyclopedia of Microbiology, M. Schaechter, Ed. p. 507-516.

Drlica, K., Zhao, X., and Malik, M. (2009) Pathogenesis: Quinolones In Encyclopedia of Microbiology, M. Schaechter, Ed. p. 707-716.

Drlica, K., Wang, J.-Y., Malik, M., Lu, T., Logan, C., Park, S., Li, X., Perlin, D., Zhao, X. (2008). An anti-mutant approach for antimicrobial use. In Antimicrobial Resistance and Implications for the 21st Century, I. Fong, K. Drlica, eds. Springer: New York. p. 371-400.

Wang. J.-Y. and Drlica, K. (2007) Selection of Target Sites in RNA for Antisense Agents. In Antisense Elements (Genetics) Research Focus, Ed.: A.G. Hernandez. Nova Science Publishers, Inc. p. 71-89.

Drlica, K., Lu, T., Malik, M., and Zhao, X. (2004). Fluoroquinolones as antituberculosis agents. In Tuberculosis, W. Rom and S. Garay, eds. pp. 791-807.

Drlica, K. and Hooper, D. (2003). Mechanism of quinolone action. In The Quinolones, D. Hooper, ed. American Soc. Microbiology: Washington, pp.19-40.

Drlica, K. and Zhao, X. (2003). Controlling antibiotic resistance: strategies based on the mutant selection window. In Re-emergence of established microbial pathogens in the 21st century, I.W. Fong and K. Drlica, eds., Kluwer Academic Plenum Publishers, pp. 295-331.

Drlica, K. and Gennaro, M. (2001). Plasmids. In Encyclopedia of Genetics, S. Brenner and J. Miller, editors-in-chief, Academic Press pp. 1485-1490.

Drlica, K. and Bendich, A. (2000). Chromosome, Bacterial. In Encyclopedia of Microbiology, J. Lederberg, ed. second edition; p. 808-821.

Drlica, K., Wu, E.-D., C.-R. Chen, J.-Y. Wang, Zhao, X., Xu, C., Qiu, L., Malik, M., Kayman, S., and Friedman, M. (1999). Prokaryotic DNA topology. In Prokaryotic Gene Expression (Frontiers in Molecular Biology); edited by S. Baumberg, ed. pp. 141-168.

Drlica, K. and Woldringh, C. (1998).
Chromosomal organization: nucleoids, chromosomal folding, and DNA topology. In Bacterial Genomes: Physical Structure and Analysis, edited by F. de Bruijn, J. Lupski, and G. Weinstock. pp 12-22.
Drlica, K., Malik, M., Wang, J.-Y, Levitz, R., and R. Burger. (1996). The fluoroquinolones as antituberculosis agents. In Tuberculosis, edited by W. Rom and S. Garay; Little, Brown and Co, NY. 817-827.

Drlica, K. (1992). The bacterial chromosome. In Encyclopedia of Microbiology, edited by J. Lederberg 1: 517-527.

Drlica, K and Riley, M. (1990).
An historical introduction to the bacterial chromosome. In The Bacterial Chromosome, K. Drlica and M. Riley, eds, American Society for Microbiology: Washington, D.C. pp. 3-13.

Drlica, K., Pruss, G., Burger, R. Franco, R., Hsieh, L., and Berger, B. (1990). Roles of DNA topoisomerases in bacterial chromosome structure and function. In The Bacterial Chromosome, K. Drlica and M. Riley, eds, American Society for Microbiology: Washington, D.C. pp. 195-204.

Drlica, K., Coughlin, S., and Gennaro, M. (1990). Mode of action of quinolones: biochemical aspects. In The New Generation of Quinolones, J. Domagala, C. Heifetz, and C. Siporin, eds., Marcel Dekker Press pp. 45-62.

Drlica, K. (1990). Genetic Engineering: The Gene. In Comprehensive Medicinal Chemistry, Volume 1; P.D. Kennewell, editor. Pergamon Press. p. 361-408.

Drlica, K. (1987). The Nucleoid. In Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, F. Neidhardt, ed. 91-103.

Symposium Chapters

Drlica, K., and Zhao., X. (2008). Mutant selection window hypothesis: a framework for anti-mutant dosing of antimicrobial agents. In National Institute of Allergy and Infectious Diseases, NIH Volume 1, Frontiers in Research, V. Georgiev, Editor. Humana Press Inc., Totawa, NJ. pp 101-106.

Drlica, K. (1999). Mechanisms of fluoroquinolone action and resistance. In First International Moxifloxacin Symposium, Berlin, 1999; L. Mandell, Ed. pp 75-83.

Burger, R., and Drlica, K. (1996). Bleomycin reaction pathways: kinetic approaches. In DNA Cleavers and Chemotherapy of Cancer or Viral Diseases, edited by B. Meunier, Kluwer Academic Publishers, Dordrecht, pp 91-106.

Rouviere-Yaniv, J., Kiseleva, E., Almeida, A., and Drlica, K. (1992). Protein HU and DNA supercoiling. In Prokaryotic Structure and Function: A New Perspective, edited by. S. Mohan, C. Dow, and J. Cole. Soc. for General Microbiol. Symp. 47:414-438.

Hsieh, L.-S., Burger, R.M., and Drlica, K. (1990). DNA topoisomerases and the bacterial chromosome. In Structural and Organizational Aspects of Metabolic Regulation, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 134, P. Srere, M.E. Jones, and C. Mathews, eds., Alan R. Liss, Inc., New York, NY pp. 153-164.

Franco, R., T. Steck, S. Chevalier, and K. Drlica. (1987). Bacterial topoisomerase mutations: effects on abundance of proteins and suppression of gyrB by rpoB. In Mechanisms of DNA Replication and Recombination, UCLA Symposia on Molecular and Cellular Biology, New Series. 47: 533-541.

Drlica, K., G. J. Pruss, S. H. Manes, and S. G. Chevalier. (1986). DNA topoisomerase mutations in bacteria. In Bacterial Chromatin, C. Gualerzi, ed. Springer-Verlag. pp. 52-63.

Drlica, K. and A. Worcel. (1975). Viscometric analysis of conformational transitions in the Escherichia coli chromosome. DNA Replication: ICN-UCLA Symposium on Molecular Biology (F. Fox and P. Hanawalt, eds.). pp 138-158.

Books Authored

Drlica, K., and Perlin, D.S. (2011). Antibiotic Resistance. (FT Press: Science)

Drlica, K. (2003). Understanding DNA: A Guide for the Curious. (John Wiley & Sons, Fourth Edition)

Drlica, K. (1997). Understanding DNA: A Guide for the Curious. (John Wiley & Sons, Third Edition).

Drlica, K. (1996). Double-Edged Sword: The Promises and Risks of the Genetic Revolution. Addison-Wesley 242 pp. (revised paperback edition).

Drlica, K. (1994). Double-Edged Sword: The Promises and Risks of the Genetic Revolution. Addison-Wesley 242 pp.

Drlica, K. (1992). Understanding DNA and Gene Cloning: A Guide for the Curious. John Wiley & Sons, 2nd edition 240 pp. (edtions in English and German).

Drlica, K. (1984). Understanding DNA and Gene Cloning: A Guide for the Curious. John Wiley and Sons, Inc. 205 pp. (editions in English, Japanese, and Italian).

Books Edited

Fong, I.W. and Drlica, K. eds. (2008). Antimicrobial Resistance and Implications for the 21st Century Springer Science+Business Media, pp 407.

Fong, I.W., and Drlica, K. eds. (2003). Re-emergence of established microbial pathogens in the 21st century. Kluwer/Plenum Press, pp. 367.

Drlica, K. and Riley, M., eds. (1990). The Bacterial Chromosome. American Society of Microbiology: Washington 469 pp.

Other Sponsored Work

Wang, X. and Zhao, X. (2009). Contribution of oxidative damage to antibiotic lethality. Antimicrob. Agents Chemother. 53:1395-1402.

Wu, X., Wang, H., and Zhao, X. (2008). Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution. Antimicrob. Agents Chemonther. 52: 3826-3827.

Zhao X. (2003). Clarification of MPC and the mutant selection window concept. J Antimicrob Chemother. 2003 Oct;52(4):731; author reply 732-3. Epub 2003 Sep 12. PMID: 12972446

Lu, T., Malik, M., and Drlica-Wagner, A. (2001). C-8-methoxy fluoroquinolones. Research Advances in Antimicrobial Agents & Chemother. 2001;2:29-42.

Wang, J.-Y. (1998). Mathematical relationships among DNA supercoiling, cation concentration, and temperature for prokaryotic transcription. Mathematical Biosciences. 1998;151:155-63.

Pruss, G. (1985). DNA topoisomerase I mutants: increased heterogeneity in linking number and other replicon-dependent changes in DNA supercoiling. J. Mol. Biol. 1985;185:51-63.

     Copyright © 2018 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101